Our finding of the associated reduction in PBC risk in BRCA2 carriers is in keeping with a recent publication by Mavaddat et al. 2020 [97], which reported a reduction in PBC risk after >5 years (but not ≤5 years) following RRSO in BRCA2 carriers (HR 0.51, 95%CI 0.26–0.99). This evidence concerns the gene BRCA2 and primary biliary cholangitis.